HK1082497A1 - Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative - Google Patents

Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative

Info

Publication number
HK1082497A1
HK1082497A1 HK06102523A HK06102523A HK1082497A1 HK 1082497 A1 HK1082497 A1 HK 1082497A1 HK 06102523 A HK06102523 A HK 06102523A HK 06102523 A HK06102523 A HK 06102523A HK 1082497 A1 HK1082497 A1 HK 1082497A1
Authority
HK
Hong Kong
Prior art keywords
benzenesulfonate
fluoro
cyanopyrrolidine derivative
cyanopyrrolidine
derivative
Prior art date
Application number
HK06102523A
Other languages
English (en)
Inventor
Hiroshi Fukushima
Akira Hiratate
Masato Takahashi
Kazuya Kameo
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of HK1082497A1 publication Critical patent/HK1082497A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
HK06102523A 2002-08-29 2006-02-24 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative HK1082497A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002249821 2002-08-29
PCT/JP2003/010828 WO2004020407A1 (ja) 2002-08-29 2003-08-27 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩

Publications (1)

Publication Number Publication Date
HK1082497A1 true HK1082497A1 (en) 2006-06-09

Family

ID=31972599

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102523A HK1082497A1 (en) 2002-08-29 2006-02-24 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative

Country Status (19)

Country Link
US (1) US7304166B2 (ru)
EP (1) EP1535907A4 (ru)
JP (1) JP3746063B2 (ru)
KR (1) KR100582141B1 (ru)
CN (1) CN1310885C (ru)
AU (1) AU2003261748B2 (ru)
BR (1) BR0313831A (ru)
CA (1) CA2496623C (ru)
EA (1) EA007613B1 (ru)
EC (1) ECSP055708A (ru)
HK (1) HK1082497A1 (ru)
HR (1) HRP20050205A2 (ru)
MX (1) MXPA05002253A (ru)
NO (1) NO20050867L (ru)
NZ (1) NZ538956A (ru)
PL (1) PL374664A1 (ru)
UA (1) UA78104C2 (ru)
WO (1) WO2004020407A1 (ru)
ZA (1) ZA200501418B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1852419A4 (en) 2005-01-27 2009-03-04 Mitsui Chemicals Inc PROCESS FOR PREPARING A FLUORINATED PROLIN DERIVATIVE
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
BRPI0609580A2 (pt) 2005-03-22 2010-04-20 Hoffmann La Roche composto, polimorfo cristalino, processo para a sua manufatura, composições farmacêuticas que o contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização do composto
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101652147B (zh) 2007-04-03 2013-07-24 田边三菱制药株式会社 二肽基肽酶iv抑制化合物和甜味剂的并用
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP3107784B2 (ja) 1996-12-26 2000-11-13 宇部興産株式会社 光学活性ピペリジン誘導体の酸付加塩及びその製法
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
US6252063B1 (en) 1998-12-01 2001-06-26 Merck & Co., Inc. Crystalline salts of a carbapenem antibiotic
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives

Also Published As

Publication number Publication date
UA78104C2 (en) 2007-02-15
EA007613B1 (ru) 2006-12-29
CN1310885C (zh) 2007-04-18
JP3746063B2 (ja) 2006-02-15
AU2003261748B2 (en) 2006-11-23
NO20050867L (no) 2005-02-18
AU2003261748A1 (en) 2004-03-19
HRP20050205A2 (en) 2005-10-31
CA2496623C (en) 2008-02-12
PL374664A1 (en) 2005-10-31
CN1678575A (zh) 2005-10-05
EA200500420A1 (ru) 2005-08-25
ZA200501418B (en) 2006-10-25
KR100582141B1 (ko) 2006-05-22
JPWO2004020407A1 (ja) 2005-12-15
CA2496623A1 (en) 2004-03-11
BR0313831A (pt) 2005-07-05
KR20050059094A (ko) 2005-06-17
US7304166B2 (en) 2007-12-04
ECSP055708A (es) 2005-08-11
EP1535907A4 (en) 2006-11-29
NZ538956A (en) 2006-08-31
WO2004020407A1 (ja) 2004-03-11
MXPA05002253A (es) 2005-06-08
US20060106087A1 (en) 2006-05-18
EP1535907A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
HK1082497A1 (en) Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
HUS1400037I1 (hu) Új 2-piridiletilbenzamid származékok
ZA200500294B (en) Novel 2-pyridylethylbenzamide derivative
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003202924A1 (en) Variation of neural-stimulation parameters
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
AU2003268687A1 (en) Novel salt of 2-acylaminothiazole derivative
AU2002314566A8 (en) Novel curcumin derivatives
EP1498420A4 (en) phospholipid
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003231370A1 (en) Amide derivatives
AU2003216848A1 (en) Deracemisation of amines
AU2003229459A1 (en) Methods of using thiazolidinedithione derivatives
AU2003235889A1 (en) Amide derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
AU2003266714A8 (en) Phospholipid derivative
GB0213488D0 (en) 2-Naphthamide derivatives
AU2002359458A1 (en) Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
AU2003291021A1 (en) Arylpyridine compounds
AU2003261875A1 (en) Amine derivative
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110827